Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Operating Leases (2023 - 2026)

Camp4 Therapeutics' Operating Leases history spans 3 years, with the latest figure at $1.7 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 69.27% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a 69.27% decrease, with the full-year FY2025 number at $1.7 million, down 69.27% from a year prior.
  • Operating Leases hit $1.7 million in Q4 2025 for Camp4 Therapeutics, down from $6.3 million in the prior quarter.
  • Over the last five years, Operating Leases for CAMP hit a ceiling of $8.5 million in Q4 2023 and a floor of $1.7 million in Q4 2025.
  • Historically, Operating Leases has averaged $6.1 million across 3 years, with a median of $6.3 million in 2024.
  • The widest YoY moves for Operating Leases: up 0.03% in 2025, down 69.27% in 2025.
  • Tracing CAMP's Operating Leases over 3 years: stood at $8.5 million in 2023, then tumbled by 35.28% to $5.5 million in 2024, then tumbled by 69.27% to $1.7 million in 2025.
  • Business Quant data shows Operating Leases for CAMP at $1.7 million in Q4 2025, $6.3 million in Q3 2025, and $7.0 million in Q2 2025.